R. Dienstmann

Artificial intelligence in oncology: from isolated task-specific tools toward integrated decision support systems

Real-world performance of next-generation sequencing in advanced non-squamous non-small cell lung cancer in Brazil.

Laboratory workflow optimization, particularly the adoption of hybrid-capture methodology, significantly improved NGS success rates in a nationwide nsNSCLC testing program, highlighting the need for targeted education and infrastructural investment to broaden equitable access to precision oncology in Brazil.

Worldwide Innovative Network Consortium: Building a Common Global Cancer Database

A narrative review of emerging cancer treatment data, molecular profiling technologies, and existing clinicogenomic databases, focusing on how tumors are characterized, how subgroups are defined, and how demographic, lifestyle, and environmental factors are captured.

Efficacy Is Impacted by

Dual MEK and mTORC1/2 blockade resulted in synergistic antiproliferative effects in cell lines bearing alterations in KRAS/BRAF and PIK3CA/PTEN and a marked proapoptotic response to therapy was observed exclusively in wild-type TP53 colorectal cancer models.

AI-based augmentation of oncology clinical trials.

It is argued that achieving the potential of AI in oncology clinical trials will require rigorous prospective validation, harmonized regulatory standards, and coordination among clinicians, trialists, regulators, industry and patients.